Status:
TERMINATED
Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion
Lead Sponsor:
Università degli Studi dell'Insubria
Collaborating Sponsors:
Alfa Wassermann, Bologna, Italy
Conditions:
Retinal Vein Occlusion
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
Retinal vein occlusion (RVO) is the second commonest retinal disease after diabetic retinopathy, and is a common cause of unilateral visual loss. There are two aims in the management of RVO: the ident...
Eligibility Criteria
Inclusion
- Age between 18 and 85 years
- A body weight of greater than 50 Kg
- A requirement that no more than 15 days had passed between symptomatic presentation, confirmation of RVO and entry into the study.
Exclusion
- Modification of the optic media transparency that could compromise the evaluation of fluorescein angiography, such as cataract or corneal degeneration
- History of major ocular surgery (with the exclusion of cataract extraction)
- Previous RVO
- Other ocular conditions that, in the opinion of the investigator, could have affected macular edema or altered visual acuity during the course of the study - Contraindications to the study drugs (e.g. major bleeding or neurosurgical procedures in the previous 3 months, serum creatinine levels of greater than 2.0 mg/dL, severe liver insufficiency, platelet count \< 100,000 mm3, known active peptic gastric ulcer)
- Active malignancy
- Pregnancy
- Inability to attend for follow up or anticipated non-compliance
- Ongoing treatment with aspirin or anticoagulant drugs at the time of RVO diagnosis
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00732927
Start Date
July 1 2002
End Date
September 1 2007
Last Update
August 12 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Insubria
Varese, Italy, 21100